A mouse tumor-derived osteolytic factor stimulates bone resorption by a mechanism involving local prostaglandins production in bone.
Culture medium which was conditioned by tissue of a CE mouse breast tumor in vitro contained dose-dependent osteolytic activity. The osteolytic activity was not soluble in dichloromethane and ethylacetate, indicating that it was not attributable to vitamin D metabolites or prostaglandins. However, breast tumor-conditioned medium stimulated production and release of prostaglandin E2 from mouse calvaria in vitro, and the stimulation of bone resorption in vitro by breast tumor-conditioned medium was blocked by a dose of indomethacin that prevented stimulation of mouse calvarial prostaglandin E2 production and release. The resorptive activity of parathyroid hormone (PTH) was not affected by the same dose of indomethacin, suggesting that the osteolytic factor was not PTH. This was further supported by observation that mouse kidney cell cAMP production was stimulated by PTH, but not by the aqueous phase of ethylacetate-extracted breast tumor-conditioned medium. In addition to osteolytic activity, breast tumor-conditioned medium contained a dose-dependent bone cell mitogenic activity, demonstrated by the stimulation of [3H]thymidine incorporation into trichloroacetic acid-insoluble macromolecules and a corresponding increase in bone cell number in monolayer cultures of bone cells. Breast tumor-conditioned medium also contained a dose-dependent transforming growth factor-(TGF-) like activity as defined by its ability to transform anchorage-dependent growth of nontransformed cells to anchorage-independent growth. The TGF in breast tumor-conditioned medium did not compete with epidermal growth factor (EGF) for EGF receptor binding, but its transforming activity was greatly enhanced by EGF, indicating that it was a beta-type TGF. Both the osteolytic and mitogenic activities were nondialyzable, sensitive to reducing agent, and not removable by dichloromethane and ethylacetate extractions. Furthermore, the TGF activity was not removed by ethylacetate extraction. Thus, the possibility that these activities in breast tumor-conditioned medium might be mediated by the same molecule must be considered. In summary, our data suggest that the CE mouse mammary carcinoma cells produce and secrete into the culture medium an osteolytic factor which is neither PTH nor prostaglandin and which stimulates local synthesis in bone of prostaglandin E2 which in turn increases bone resorption in vitro.
Lau
K H
KH
Lee
M Y
MY
Linkhart
T A
TA
Mohan
S
S
Vermeiden
J
J
Liu
C C
CC
Baylink
D J
DJ
D000818:Animals; D000831:Animals, Newborn; D001862:Bone Resorption; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D002294:Carcinoma, Squamous Cell; D002460:Cell Line; D003470:Culture Media; D000242:Cyclic AMP / Q000378:metabolism; D004261:DNA Replication; D015232:Dinoprostone; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D007668:Kidney; D008325:Mammary Neoplasms, Experimental / Q000503:physiopathology*; D051379:Mice; D009924:Organ Culture Techniques; D010014:Osteolysis; D010455:Peptides / Q000494:pharmacology / Q000502:physiology*; D011458:Prostaglandins E / Q000096:biosynthesis*; D051381:Rats; D011956:Receptors, Cell Surface / Q000378:metabolism; D015291:Transforming Growth Factors
D003470:Culture Media; D006133:Growth Substances; D010455:Peptides; D011458:Prostaglandins E; D011956:Receptors, Cell Surface; D004815:Epidermal Growth Factor; D015291:Transforming Growth Factors; D000242:Cyclic AMP; D066246:ErbB Receptors; D015232:Dinoprostone; D002118:Calcium